These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 30101837)

  • 1. Dihydroartemisinin represses osteoclastogenesis of bone marrow macrophages through reduced NFATc1 expression and impaired phosphorylation of IκBα.
    Komaki S; Sakai E; Fukuma Y; Nishishita K; Okamoto K; Tsukuba T
    Biomed Res; 2018; 39(4):169-177. PubMed ID: 30101837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα.
    Ma Z; Yu R; Zhao J; Sun L; Jian L; Li C; Liu X
    Inflamm Res; 2019 Feb; 68(2):157-166. PubMed ID: 30604211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docosahexaenoic acid signaling attenuates the proliferation and differentiation of bone marrow-derived osteoclast precursors and promotes apoptosis in mature osteoclasts.
    Kim HJ; Ohk B; Yoon HJ; Kang WY; Seong SJ; Kim SY; Yoon YR
    Cell Signal; 2017 Jan; 29():226-232. PubMed ID: 27836739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dihydroartemisinin attenuates osteoclast formation and bone resorption via inhibiting the NF‑κB, MAPK and NFATc1 signaling pathways and alleviates osteoarthritis.
    Ding D; Yan J; Feng G; Zhou Y; Ma L; Jin Q
    Int J Mol Med; 2022 Jan; 49(1):. PubMed ID: 34738623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The coffee diterpene kahweol prevents osteoclastogenesis via impairment of NFATc1 expression and blocking of Erk phosphorylation.
    Fumimoto R; Sakai E; Yamaguchi Y; Sakamoto H; Fukuma Y; Nishishita K; Okamoto K; Tsukuba T
    J Pharmacol Sci; 2012; 118(4):479-86. PubMed ID: 22447306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of tert-butylhydroquinone on osteoclast differentiation via up-regulation of heme oxygenase-1 and down-regulation of HMGB1 release and NFATc1 expression.
    Yamaguchi Y; Sakai E; Sakamoto H; Fumimoto R; Fukuma Y; Nishishita K; Okamoto K; Tsukuba T
    J Appl Toxicol; 2014 Jan; 34(1):49-56. PubMed ID: 23112101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
    Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
    Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
    Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coenzyme q10 regulates osteoclast and osteoblast differentiation.
    Moon HJ; Ko WK; Jung MS; Kim JH; Lee WJ; Park KS; Heo JK; Bang JB; Kwon IK
    J Food Sci; 2013 May; 78(5):H785-891. PubMed ID: 23582186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrolactin F inhibits RANKL-mediated osteoclastogenesis by suppressing Akt, MAPK and NFATc1 pathways and promotes osteoblastogenesis through a BMP-2/smad/Akt/Runx2 signaling pathway.
    Li L; Sapkota M; Gao M; Choi H; Soh Y
    Eur J Pharmacol; 2017 Nov; 815():202-209. PubMed ID: 28919027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. G protein-coupled receptor 84 controls osteoclastogenesis through inhibition of NF-κB and MAPK signaling pathways.
    Park JW; Yoon HJ; Kang WY; Cho S; Seong SJ; Lee HW; Yoon YR; Kim HJ
    J Cell Physiol; 2018 Feb; 233(2):1481-1489. PubMed ID: 28574596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).
    Chaweewannakorn W; Ariyoshi W; Okinaga T; Fujita Y; Maki K; Nishihara T
    J Cell Physiol; 2019 Feb; 234(2):1745-1757. PubMed ID: 30105896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
    Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
    J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The natural flavonoid galangin inhibits osteoclastic bone destruction and osteoclastogenesis by suppressing NF-κB in collagen-induced arthritis and bone marrow-derived macrophages.
    Huh JE; Jung IT; Choi J; Baek YH; Lee JD; Park DS; Choi DY
    Eur J Pharmacol; 2013 Jan; 698(1-3):57-66. PubMed ID: 22985747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.